XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY

XOMA Royalty Corp

Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.
Repurchased 648,048 shares for $16.0M; completed seven acquisitions adding 22 assets to portfolio.
Pipeline catalysts: volixibat Phase 2b data in PSC in Q2 2026; ersodetug Phase 3 data in tumor HI 2H 2026.
Seralutinib Phase 3 PAH missed primary endpoint; path forward discussions with FDA ongoing.
Litigation vs Janssen over TREMFYA IP continues; G&A includes $1.1M legal costs in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.